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1 Glossary of Terms: Vision Screening 
Abnormal test result ƚĞƐƚƌĞƐƵůƚǁŚĞƌĞĂŶŽƌŵĂů ?ƉĂƐƐ ?ƌĞƐƉŽŶƐĞĐŽƵůĚŶŽƚďĞ
detected under good conditions. The result on screening 
ĞƋƵŝƉŵĞŶƚŵĂǇŝŶĚŝĐĂƚĞ ?ŶŽƌĞƐƉŽŶƐĞ ? ? ?ĨĂŝů ? ?Žƌ ?ƌĞĨĞƌ  ?
Attendance rate The proportion of all those invited for screening that are tested 
and receive a result: 
 
x Invited for screening includes all those that are offered 
the screening test. 
x dĞƐƚĞĚĂŶĚƌĞĐĞŝǀĞĂƌĞƐƵůƚĐŽƵůĚďĞĂ ?ƉĂƐƐ ?Žƌ ?ƌĞĨĞƌƌĂů
ƚŽĚŝĂŐŶŽƐƚŝĐĂƐƐĞƐƐŵĞŶƚ ? ?
 
Attendance rate provides information on the willingness of 
families to participate in screening. 
Compliance with 
referral (percentage) 
The percentage of those who are referred from screening to a 
diagnostic assessment that actually attend the diagnostic 
assessment. 
 
Percentage of compliance provides information on the 
willingness of families to attend the diagnostic assessment after 
referral from screening. 
Coverage The proportion of those eligible for screening that are tested and 
receive a result: 
 
x Eligible for screening includes those within the population 
that are covered under the screening or health care 
programme. 
x dĞƐƚĞĚĂŶĚƌĞĐĞŝǀĞĂƌĞƐƵůƚĐŽƵůĚďĞĂ ?ƉĂƐƐ ?Žƌ ?ƌĞĨĞƌƚŽ
ĚŝĂŐŶŽƐƚŝĐĂƐƐĞƐƐŵĞŶƚ ? ? 
 
Factors such as being offered screening, willingness to 
participate, missed screening, ability to complete the screen, and 
ability to document the screening results will influence the 
coverage. 
False negatives The percentage of children with a visual deficit (defined by the 
ƚĂƌŐĞƚĐŽŶĚŝƚŝŽŶ ?ƚŚĂƚƌĞĐĞŝǀĞĂƌĞƐƵůƚŽĨ ?ƉĂƐƐ ?ĚƵƌŝŶŐƐĐƌĞĞŶŝŶŐ ? 
 
Example: If 100 children with visual deficit are screened, and 1 
child passes the screening, the percentage of false negatives is 
1%. 
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False positives The percentage of children with normal vision that are referred 
from screening to a diagnostic assessment. 
Guidelines Recommendations or instructions provided by an authoritative 
body on the practice of screening in the country or region. 
Vision screening 
professional 
A person qualified to perform vision screening, according to the 
practice in the country or region. 
Inconclusive test 
result 
ƚĞƐƚƌĞƐƵůƚǁŚĞƌĞĂŶŽƌŵĂů ?ƉĂƐƐ ?ƌĞƐƉŽŶƐĞĐŽƵůĚŶŽƚďĞ
detected due to poor test conditions or poor cooperation of the 
child.  
Invited for screening Infants/children and their families who are offered screening. 
Outcome of vision 
screening 
An indication of the effectiveness or performance of screening, 
such as a measurement of coverage rate, referral rate, number of 
children detected, etc. 
Untreated amblyopia Those children who have not received treatment for amblyopia 
due to missed screening or missed follow-up appointment. 
Persistent amblyopia Amblyopia that is missed by screening, or present after the child 
has received treatment. 
Positive predictive 
value 
The percentage of children referred from screening who have a 
confirmed vision loss. 
 
For example, if 100 babies are referred from screening for 
diagnostic assessment and 10 have normal vision and 90 have a 
confirmed visual defect, the positive predictive value would be 
90%. 
Prevalence The percentage or number of individuals with a specific disease 
or condition. Prevalence can either be expressed as a percentage 
or as a number out of 1000 individuals within the same 
demographic. 
Programme An organised system for screening, which could be based 
nationally, regionally or locally. 
Protocol Documented procedure or sequence for screening, which could 
include which tests are performed, when tests are performed, 
procedures for passing and referring, and so forth. 
Quality assurance A method for checking and ensuring that screening is functioning 
adequately and meeting set goals and benchmarks. 
Referral criteria A pre-determined cut-off boundary for when a child should be 
re-tested or seen for a diagnostic assessment.  
Risk babies / Babies 
at-risk 
All infants that are considered to be at-risk or have risk-factors 
for vision defects/ophthalmic pathology according to the 
screening programme. 
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Two common risk factors are admission to the neonatal-intensive 
care unit (NICU) or born prematurely. However, other risk factors 
for visual defects may also be indicated in the screening 
programme. 
Sensitivity The percentage of children with visual defects that are identified 
via the screening programme. 
 
For example, if 100 babies with visual defects are tested, and 98 
of these babies are referred for diagnostic assessment and 2 pass 
the screening, the sensitivity is 98%. 
Specificity The percentage of children with normal vision that pass the 
screening. 
 
For example, if 100 babies with normal vision are tested, and 10 
of these babies are referred for diagnostic assessment and 90 
pass the screening, the specificity is 90%. 
Target condition The visual defect you are aiming to detect via the screening 
programme. 
Well, healthy babies Infants who are not admitted into the NICU or born prematurely 
(born after a gestation period of less than 37 weeks).  
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2 Abbreviations 
ACT  Alternating Cover Test 
AR  Autorefraction 
AS  Automated Screening 
CT  Cover Test 
CV  Colour Vision 
EI Eye Inspection 
EM  Eye Motility 
Fix  Fixation 
GDP  Gross Domestic Product 
GP General Practitioner 
Hir  Hirschberg test 
NICU Neonatal-intensive care unit 
PM Pursuit Movements 
PMI Protection Maternelle et Infantile 
PPP  Purchasing Power Parity 
PR  Pupillary Reflexes 
RE  Retinal Examination 
ROP Retinopathy of Prematurity 
RR  Red Reflex Testing 
SV  Stereopsis 
VA  Visual Acuity  
WHO  World Health Organisation 
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3 Population and Healthcare Overview 
The population of France is 67,118,648 (World Bank, 2018a) and birth rate is estimated at 
11.7 births/1,000 population in 2016 (World Bank, 2018b).The change in population and 
birth rate from 1960 to 2017 is shown in Figure 1, graphs A and B respectively. 
France has a reported population density of 123 people per square kilometre in 2017 and 
this has risen from 87 people per square kilometre in 1961 (World Bank, 2018c). Infant 
mortality in 2017 is estimated at 3.5 deaths/1,000 live births in total (World Bank, 2018d). 
The average life expectancy in France is estimated at 82.3 years (World Bank, 2018e), with 
a death rate 8.8 deaths/1,000 population in 2016 (World Bank, 2018f). France has a gross 
national income per capita (PPP int. $, 2013) of $37,000 (WHO, 2016). The estimated total 
expenditure on health per capita in 2014 was $4,508 (Intl $) and the total expenditure on 
health in 2014 as percentage of GDP was 11.5% (WHO, 2016). 
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Figure 1: Change in the Total Population and Birth Rate in France between 1960 and 2017 
 
Source: Information sourced from World Bank (2018)
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4 Vision Screening Commissioning and Guidance 
Vision screening is organised both nationally and regionally, with 4600 PMI (Protection 
Maternelle et Infantile (Maternal and child protection centres). The maternal and child 
protection centres (PMI) are public health services where parents can go during the 
pregnancy and until the child is 6 years of age, to receive advice and medical care. All regions 
provide vision screening and there are no differences in protocols between regions. The 
national general health screening guideline is used to inform vision screening in France.  
Vision screening is funded by health insurance, the council, municipalities, the state, 
provinces and regions. There are no differences in funding methods between regions and all 
vision screening is embedded into a general preventative child health care screening 
programme.  
The content of this vision screening programme is determined by the French Public Agency 
HAS and the French Health Ministry. It is not known exactly when the vision screening 
programme was initiated, but it has been implemented for a long time. It has been changed 
since its application. In 2006 the version of the health book (Carnet de Santé) provided more 
detail for vision screening. In April 2018, the latest version of the health book (Carnet de 
Santé), made some recommendations includŝŶŐ ? ?ĞĨŽƌĞƚŚƌĞĞǇĞĂƌƐ ?ĂǀŽŝĚƉƵƚƚŝŶŐǇŽƵƌĐŚŝůĚ
in a room where the television is lit, even if he does not look at it " and "Do not give him a 
tablet or smartphone to calm him, during his meals, or before his sleep".  
Vision screening is conducted by ophthalmologists, orthoptists, paediatricians, general 
physicians (GP) and nurses in hospitals, child health care centres, kindergarten, public places 
and schools. It is unknown how many vision screening professionals there are in France per 
million population. Nurses and opticians do not screen, but are general professionals that 
could screen with additional training. Currently, only orthoptists receive specific accredited 
training for vision screening. There is no other training for vision screening available. 
There is no regularity regarding how often vision screening is reviewed, any revisions are 
decided upon by the French Public Agency HAS and the French Health Ministry. Funding for 
review comes from the French Public Agency HAS and free expert input. There are no 
methods for quality monitoring of vision screening imposed by the government, however, 
information is collected by the National Institute of Demographic Studies (Institut National 
Ě ?ƚƵĚĞƐĠŵŽŐƌĂƉŚŝƋƵĞƐ ?INED). It is a French public institution specialised in demographic 
research and population studies. No vision screening research has been conducted in France 
and there has been no cost-effective analysis of the vision screening programme.  
 
 
Summary Vision Screening Data: France                                                                                           
4 
 
5 Screening programme  
The target conditions screened for include any structural abnormality, pathology, strabismus, 
and reduced visual acuity. The health care professionals delivering vision screening, venue for 
screening and tests used vary depending on the age of the child as shown in Tables 1, 2 and 
3 respectively. Specific details of the screening offered within each age group are described 
more fully in sections 5.1 to 5.4 below. 
5.1 Vision screening - Preterm babies 
Preterm babies up to the age of 3 months are screened by paediatricians, GPs, orthoptists or 
ophthalmologists in hospitals, private practice and PMI centres. This is completed using a 
battery of tests including eye inspection, fixation, red reflex testing, eye motility, Hirschberg 
test, retinal examination, pursuit movements and pupillary reflexes. It is unknown after how 
many abnormal or inconclusive test results a baby is referred for further examination.  
5.2 Vision screening - Birth to 3 months 
Well, healthy babies up to the age of 3 months are screened by paediatricians, 
ophthalmologists or orthoptists in hospitals, child health care centres and private clinics. This 
is completed by eye inspection, fixation, red reflex testing (ophthalmologist), eye motility, 
Hirschberg test, pursuit movements and pupillary reflexes. Tests are performed at birth and 
then again at 2 months. A child is referred after one abnormal result and screening is repeated 
at the next examination if the screening is inconclusive. The referral criteria for this age 
category is not defined as it is at the discretion of the examiner. 
5.3 Vision screening - 3 months to 36 months 
At age 3 to 36 months, vision screening is conducted by either a paediatrician, nurse, 
specialist, nurse, ophthalmologist, orthoptist or GP. This takes place in hospitals, PMI or 
private practices using eye inspection, fixation, red reflex testing, eye motility, Hirschberg 
test, pursuit movements, pupillary reflexes, cover test, alternating cover test, visual acuity 
(VA), stereopsis (Lang) and colour vision. Children are tested at 4 months, 9 months and 24 
months.  
A VA measurement is conducted by either a nurse, orthoptist, ophthalmologist, GP or 
paediatrician, for the first time at 24 months, using HOTV or Numbers. The specific charts 
used include Numbers, CADET Tests, or STYCAR. It is unknown after how many abnormal or 
inconclusive test results a child is referred for further examination. The referral criteria for 
this age category is not defined as this is at the discretion of the examiner, but this is usually 
in the event of any abnormality. 
5.4 Vision screening - 36 months to 7 years 
Children aged 36 months to 7 years are screened by either a paediatrician, nurse, specialist 
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nurse, ophthalmologist, orthoptist, or a GP. This takes places at schools, hospitals, PMI and 
private practices using eye inspection, fixation, red reflex testing, eye motility, Hirschberg 
test, pursuit movements, pupillary reflexes, cover test, alternating cover test, VA 
measurement, stereopsis (Lang), colour vision and automated screening (PlusOptix, Spot 
Vision Screener, 2Win). A VA measurement is conducted by either a nurse, orthoptist, 
ophthalmologist, GP or paediatrician, for the second time at 3 years of age and then a third 
time at 4 years of age, using HOTV, or Numbers. The specific charts used include:  
 
x Ophthalmologists: Monoyer Test, Numbers, E letters, Pigassou test, CADET Tests  
x Orthoptists: Numbers, E letters, CADET Tests or STYCAR  
x GPs: CADET Tests or STYCAR  
 
It is unknown after how many abnormal or inconclusive test results a child is referred for 
further examination as this is at the discretion of the examiner. 
 
 
 
 
Summary Vision Screening Data: France                                                                                                    
6 
 
Table 1: Healthcare professionals who conduct vision screening in each age group  
Table 1 Paediatrician Nurse Specialist nurse Ophthalmologist Orthoptist GP 
Preterm babies  9 × × 9 9 9 
0 to 3 months  9 × × 9 9 × 
3 to 36 months  9 9 9 9 9 9 
3 to 7 years  9 9 9 9 9 9 
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Table 2: Vision screening tests used in vision screening for each age group  
Table 2 
EI Fix RR EM Hir RE PM PR CT ACT VA SV CV AS 
Preterm 
babies  
9 9 9 9 9 9 9 9 × × × × × × 
0 to 3 
months  
9 9 9 9 9 × 9 9 × × × × × × 
3 to 36 
months  
9 9 9 9 9 × 9 9 9 9 9 9 9 × 
3 to 7 years  9 9 9 9 9 × 9 9 9 9 9 9 9 9 
 
Key: EI: Eye Inspection; Fix: Fixation; RR: Red Reflex Testing; EM: Eye Motility; Hir: Hirschberg; RE: Retinal Examination; PM: Pursuit Movements; 
PR: Pupillary Reflexes; CT: Cover Test; ACT: Alternating Cover Test; VA: Visual Acuity; SV: Stereopsis; CV: Colour Vision; AS: Automated Screening 
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Table 3: Location of vision screening for each age group  
Table 3 
Child Health Care 
Centre 
Hospital Private practice PMI School 
Preterm babies  × 9 9 9 × 
0 to 3 months  9 9 9 × × 
3 to 36 months  × 9 9 9 × 
3 to 7 years  × 9 9 9 9 
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6 Automated Screening 
Automated vision screening is achieved using handheld, portable devices designed to detect 
presence of refractive error from 6 months of age. It provides objective results and is used to 
detect amblyopic risk factors. This differs from other methods used to screen children for 
amblyopia which focus on detection of the actual condition and the resulting visual loss. 
In France, automated screening devices are used from the age of 36 months. The referral 
criteria are not known. Specifically, PlusOptix, Spot Vision Screener and 2Win are devices 
utilised by orthoptists in schools or in private practice as part of vision screening. These 
devices cost approximately 6000-8000 Euros, with no maintenance costs during an initial 2-
year warranty period. Institutions replace the devices every 5-10 years. The devices have 
similar duration of functioning. 
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7 Provision for Visually Impaired  
In France, there are approximately 300 schools for the blind or severely visually impaired. The 
costs per child for these schools is unknown and whilst there is support for visually impaired 
children who attend mainstream primary school, it is unknown what this support is.  
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8 Knowledge of existing screening programme 
8.1 Prevalence/Diagnosis  
In France, the prevalence of treated or untreated amblyopia at age 7 is estimated at 5%, with 
a prevalence of persistent amblyopia at age 7 of less than 1%. The prevalence of strabismus 
at age 7 is estimated at 5%. The data available about the incidence of the four types of 
amblyopia (refractive, strabismic, combined-mechanism and deprivation) are not available. 
8.2 Coverage 
All children are invited for vision screening, the timelines of which are detailed in the Carnet 
de Santé. The use of this is reserved for health professionals and its consultation is subject to 
parental consent. This document contains the medical information needed to monitor the 
health of the child up to the age of 18 years. The method of invitation is not clear. The 
coverage and attendance of vision screening before the age of 7 years is unknown, as is the 
coverage and attendance of VA measurements as part of vision screening, before the age of 
7 years. The compliance to referral after an abnormal screening result is estimated at 90%. 
There is no registration or documentation of noncompliance with referral after an abnormal 
screening result. 
8.3 Screening evaluation 
The percentage of false negatives and false positives for vision screening is not known. The 
positive predictive value of a refer result after vision screening is also not known. The 
sensitivity and specificity of vision screening is also not known.  
8.4 Treatment success 
In France, there are 1/2000 cases of congenital cataract per year  ? it is not clear how many 
are treated. Subsequent to screening, 2% of infants are treated for strabismus before the age 
of 7 years and this number rises to 5% for children treated for strabismus overall (including 
those who miss screening) before the age of 7 years. After being screened, 1% of children are 
treated for amblyopia and overall, 3-5% of all children (including those who miss screening) 
are treated for amblyopia before the age of 7 years.  
In France, only ophthalmologists prescribe glasses for children aged less than 7 years, after 
referral from screening. In addition to this, patching, penalisation with glasses, atropine and 
cataract surgery are also treatment options practiced after an abnormal screening test result 
where appropriate. All eligible children with vision disorders are offered treatment. 
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9 Costs of vision screening in children 
9.1 Cost of vision screening  
In France, vision screening is free for parents, there is no financial reward for attending vision 
screening and there is no penalty for not attending. However, vision screening is mandatory. 
The salary costs for vision screening professionals, per year, are not known. The estimated 
salary cost per hour is 20 Euros. The costs of training the general preventative child health 
care screening professionals, between leaving secondary education and qualification are not 
known. The total screening costs per year for vision screening is estimated at 700 million 
Euros, but it is not known what the total costs per child per year are for vision screening in 
France.  
9.2 Cost of treatment for amblyopia 
The estimated costs of treating typical patients with refractive amblyopia and strabismic 
amblyopia are not known.  
9.3 Cost of Treatment for strabismus  
The estimated costs of strabismus surgery are not known.  
9.4 Cost of treatment for cataract 
The estimated costs for congenital cataract surgery, including follow up of derivation 
amblyopia are not known. 
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